Stephen Daroy
Psychiatric/Mental Health · Belleville, NJNPI 1740905652
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,754, more than ten times the $144 reported in 2023. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Johnson & Johnson$996
- Teva Pharmaceuticals USA, Inc.$802
- AbbVie$661
- E.r. Squibb & Sons, L.L.C.$390
- Otsuka America Pharmaceutical, Inc.$372
- plus $1K from 13 others
What the payments were for
- Food & beverage$5,43498%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 50 | $1,093 |
| Johnson & Johnson | 45 | $996 |
| Teva Pharmaceuticals USA, Inc. | 36 | $802 |
| AbbVie | 50 | $661 |
| E.r. Squibb & Sons, L.L.C. | 34 | $390 |
| Otsuka America Pharmaceutical, Inc. | 25 | $372 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $306 |
| Neurocrine Biosciences, Inc. | 16 | $254 |
| Lundbeck LLC | 6 | $108 |
| Bausch Health US, LLC | 6 | $104 |
| Vanda Pharmaceuticals Inc. | 6 | $97 |
| Axsome Therapeutics, Inc. | 5 | $79 |
| Neos Therapeutics, LP | 5 | $78 |
| Corium, LLC | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Indivior Inc. | 3 | $49 |
| Braeburn Inc. | 1 | $17 |
| Validus Pharmaceuticals LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,011
- INVEGA SUSTENNA$127
- INVEGA TRINZA$127
- CAPLYTA$125
- UZEDY$120
- SPRAVATO$117
How this compares
$5,545 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 144 | $413,111 |
| Invega TrinzaPaliperidone Palmitate | 15 | $131,734 |
| Abilify MaintenaAripiprazole | 23 | $63,356 |
| AristadaAripiprazole Lauroxil | 24 | $55,833 |
| Risperidone ErRisperidone Microspheres | 21 | $44,207 |
| VraylarCariprazine Hcl | 27 | $37,319 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $27,057 |
| Aripiprazole | 74 | $2,306 |
| Divalproex Sodium ErDivalproex Sodium | 56 | $1,996 |
| Divalproex Sodium | 62 | $1,819 |
| Benztropine Mesylate | 155 | $1,814 |
| Clozapine | 46 | $1,356 |
| Quetiapine Fumarate | 107 | $1,117 |
| Haloperidol | 39 | $970 |
| Haloperidol Decanoate | 46 | $949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $996 | $544,845159 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,093 | $82,88941 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $372 | $63,35623 claims |
| AbbVieVraylar | $661 | $37,31927 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $22142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Belleville
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.